atorvastatin has been researched along with Depressive Disorder in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, CY; Chen, TT; Gu, QX; Ni, HY; Yang, C; Yin, JJ; Zhou, T | 1 |
| Buss, ZS; Doneda, DL; Ferreira, YS; Fraga-Junior, EB; Lima, E; Lopes, L; Rios-Santos, F; Stupp, IJV; Taniguti, EH; Vandresen-Filho, S; Viola, GG | 1 |
2 other study(ies) available for atorvastatin and Depressive Disorder
| Article | Year |
|---|---|
Atorvastatin ameliorates depressive behaviors via regulation of α7nAChR expression by PI3K/Akt-BDNF pathway in mice.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Anticholesteremic Agents; Antidepressive Agents; Atorvastatin; Brain-Derived Neurotrophic Factor; Depressive Disorder; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2022 |
Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice.
Topics: Animals; Antidepressive Agents; Atorvastatin; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder; Disease Models, Animal; Fluoxetine; Hippocampus; Lipopolysaccharides; Male; Mice; Neuroprotective Agents; Oxidative Stress; Prefrontal Cortex; Tumor Necrosis Factor-alpha | 2019 |